Ligand Pharmaceuticals Incorporated
Ligand Pharmaceuticals Incorporated (LGND) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · LGND · as of Sep 30, 2025
Ownership Breakdown
318
Institutional Holders
▲ 46 vs Q2
$3.63B
Total Inst. Value
▲ $1.45B vs Q2
20.04M
Shares Outstanding
freeFloat 97.60%
20.51M
13F Shares Held
▲ 1.31M vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
LGND largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
TUDOR INVESTMENT CORP ET AL pharmaceutical preparations | 15.75M | 81.32% | 81.32% | $17.70B | Nov 14, 2025 | NEW |
BLACKROCK, INC. pharmaceutical preparations | 2.88M | 14.89% | 14.89% | $510.97B | Nov 12, 2025 | ▼ 29.2K |
VANGUARD GROUP INC pharmaceutical preparations | 2.08M | 10.72% | 10.72% | $367.79B | Nov 7, 2025 | ▼ 13.1K |
JANUS HENDERSON GROUP PLC pharmaceutical preparations | 1.04M | 5.38% | 5.38% | $184.65B | Nov 14, 2025 | ▼ 18.4K |
MACQUARIE GROUP LTD pharmaceutical preparations | 751.8K | 3.88% | 3.88% | $133.17B | Nov 13, 2025 | ▼ 174.8K |
STATE STREET CORP pharmaceutical preparations | 749.4K | 3.87% | 3.87% | $132.74B | Nov 14, 2025 | ▼ 394 |
CONGRESS ASSET MANAGEMENT CO /MA pharmaceutical preparations | 667.3K | 3.45% | 3.45% | $118.21B | Oct 10, 2025 | ▲ 19.4K |
CHICAGO CAPITAL, LLC pharmaceutical preparations | 568.6K | 2.94% | 2.94% | $100.72B | Oct 22, 2025 | ▼ 3.2K |
STEPHENS INVESTMENT MANAGEMENT GROUP LLC pharmaceutical preparations | 554.5K | 2.86% | 2.86% | $98.23B | Oct 28, 2025 | ▼ 50.3K |
MASSACHUSETTS FINANCIAL SERVICES CO /MA/ pharmaceutical preparations | 541.8K | 2.80% | 2.80% | $95.98B | Oct 29, 2025 | ▲ 202.1K |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
18
Increased
+1.92M shares2
New Positions
first time holders29
Decreased
−866.1K shares0
Sold Out
fully exitedNet shares change (top 50)
+1.06M
+1.92M / −866.1K
Net new holders
-9
2 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
LGND insider trading · insider activity
Source: SEC Form 4
Insiders have been primarily selling shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
7
Buy transactions
39
Sell transactions
0.18
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Reardon Andrew CLO & Secretary | Jun 1, 2026 | Sale | 491 | $223.95 | $110.0K | 45.9K | Form 4 ↗ |
Reardon Andrew CLO & Secretary | Jun 1, 2026 | Sale | 677 | $225.20 | $152.5K | 45.2K | Form 4 ↗ |
Reardon Andrew CLO & Secretary | Jun 1, 2026 | Sale | 1,432 | $225.97 | $323.6K | 43.8K | Form 4 ↗ |
Reardon Andrew CLO & Secretary | Jun 1, 2026 | Sale | 400 | $226.78 | $90.7K | 43.4K | Form 4 ↗ |
Reardon Andrew CLO & Secretary | Jun 1, 2026 | Sale | 584 | $228.57 | $133.5K | 42.8K | Form 4 ↗ |
Reardon Andrew CLO & Secretary | Jun 1, 2026 | Sale | 1,216 | $229.47 | $279.0K | 41.6K | Form 4 ↗ |
Reardon Andrew CLO & Secretary | Jun 1, 2026 | Sale | 200 | $230.41 | $46.1K | 41.4K | Form 4 ↗ |
KOZARICH JOHN W director | May 1, 2026 | Sale | 80 | $227.37 | $18.2K | 42.2K | Form 4 ↗ |
KOZARICH JOHN W director | May 1, 2026 | Sale | 1 | $229.87 | $229.87 | 42.2K | Form 4 ↗ |
KOZARICH JOHN W director | May 1, 2026 | Sale | 165 | $231.87 | $38.3K | 42.0K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Ligand Pharmaceuticals Incorporated (LGND) is primarily owned by institutional investors, who hold approximately 100.0% of total shares outstanding. Company insiders own approximately 2.40%, while retail and public investors account for the remaining 0.00%.
The largest institutional shareholder of Ligand Pharmaceuticals Incorporated is TUDOR INVESTMENT CORP ET AL, holding approximately 15.75 million shares — equal to 81.32% of outstanding shares — as of September 30, 2025.
A total of 318 institutional investors currently hold LGND stock, with a combined institutional value of approximately $3.63 billion as of the most recent 13F filing period.
Frequently asked questions
LGND ownershipLigand Pharmaceuticals Incorporated (LGND) is primarily owned by institutional investors, who hold approximately 100.0% of shares. The largest shareholder is TUDOR INVESTMENT CORP ET AL with a 81.32% stake. Company insiders hold 2.40%. Data sourced from SEC Form 13F as of September 30, 2025.